Engineered Imine Reductases for Direct Chiral Amine Synthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for efficient biocatalytic routes to synthesize chiral secondary and tertiary amines under industrially applicable conditions, as existing methods rely on chiral boron reagents or multi-step synthesis, and there is a lack of identified enzymes capable of efficiently catalyzing such reactions.
Innovation Solution
Engineered polypeptides derived from wild-type opine dehydrogenases, specifically from Arthrobacter Sp. Strain 1C, are developed to catalyze the conversion of unactivated ketones and amines into secondary or tertiary amines through direct reductive amination, exhibiting imine reductase activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If chiral boron reagents or multi-step synthesis are used to produce chiral secondary and tertiary amines, then the desired chiral amine products can be obtained, but the process complexity and number of steps increase
Solution Approach 1:
The patent divides the complex multi-step synthesis process into a single enzymatic step catalyzed by engineered imine reductases. The enzyme system selectively reduces the imine intermediate to the chiral amine product, separating the reduction step from previous complex synthetic sequences and achieving chirality control in one operation.
Solution Approach 2:
The patent replaces conventional chemical methods using chiral boron reagents with a biocatalytic system. The engineered imine reductase enzyme performs the reduction reaction with high stereoselectivity, substituting the mechanical/chemical approach with a biological catalyst that provides inherent chirality control through its active site geometry.
2Productivity
If existing chemical methods are used to synthesize chiral amines, then the products can be produced, but the efficiency and industrial applicability are limited
Solution Approach 1:
The patent modifies the enzymatic system by engineering specific amino acid residues in the imine reductase protein sequence to optimize reaction parameters. These changes enhance the enzyme's catalytic efficiency, substrate range, and stability under industrial conditions, transforming a laboratory curiosity into an industrially viable process.
Solution Approach 2:
The engineered imine reductase system demonstrates broad substrate specificity, capable of reducing various imine compounds to different chiral amine products. This multi-functionality allows a single enzyme system to serve multiple synthetic needs, improving productivity and ease of manufacture by eliminating the need for multiple specialized reagents.
3Reliability
If no efficient biocatalytic routes are used, then existing chemical methods must be employed, but the lack of identified enzymes limits biocatalytic potential
Solution Approach 1:
The patent performs preliminary enzyme engineering and characterization to establish a reliable biocatalytic route before industrial implementation. The engineered imine reductases are optimized in advance for stability, activity, and substrate specificity, ensuring that the biocatalytic route is ready for scalable production without requiring on-site enzyme development.
Solution Approach 2:
The patent identifies and utilizes imine intermediates as key players in the biocatalytic transformation. The engineered imine reductases specifically target these imine intermediates and reduce them to chiral amine products, providing a reliable and controllable pathway that bridges substrate and product while enabling broad substrate range through intermediate formation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These engineered polypeptides can efficiently convert a wide range of substrates into chiral secondary and tertiary amines, offering a stereoselective and efficient biocatalytic route for industrial applications.
Implementation Method 1
The engineered polypeptides are capable of catalyzing the conversion of a ketone substrate and an amine substrate to form a secondary or tertiary amine product compound
Implementation Method 2
The biocatalysts of the disclosure are engineered polypeptide variants derived from a wild-type gene from Arthrobacter Sp. Strain 1C which encodes an opine dehydrogenase
Data Source
AI summary
The present disclosure provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.